arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

Esperion Therapeutics, Inc.

ESPR
$3.19 0.00 (0.00%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
16 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
52
Health
Fair
Bearish
auto_awesome

Analytical Summary

Esperion Therapeutics, Inc. faces fundamental challenges with weakness in Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $663.1M
Dividend Yield —
Revenue Growth 21.3% ↘
Op. Margin 15.0% ↘
ROIC -21.7% ↘
FCF / Share $-0.06 ↗
Trailing P/E —
Price / Book —
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Jul 10, 2026.

16-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$403.13M
↑ +21.3% —
Net Income Profit after all expenses
$-22.68M
↑ +56.2% —
Operating Margin Operating profit as % of sales
15.0%
↓ -8.7% 67th
FCF / Share Free cash flow per share
$-0.06
↑ +50.8% —
Long-Term Debt Long-term obligations
$1.02M
↓ -62.0% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability ↑
35
Returns ↓
60
Financial Health
68
Cash Quality ↓
43

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 16 years · 58 quarters